

Morningstar<sup>®</sup> Document Research<sup>SM</sup>

## **FORM 10-Q**

**CardioGenics Holdings Inc. - CGNH**

**Filed: June 13, 2012 (period: April 30, 2012)**

Quarterly report with a continuing view of a company's financial position

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended April 30, 2012.

Transition report under Section 13 or 15(d) of the Exchange Act

For the transition period from \_\_\_\_\_ to \_\_\_\_\_ .

Commission file number 000-28761

**CARDIOGENICS HOLDINGS INC.**

(Exact name of registrant as specified in its Charter)

Nevada  
(State or other jurisdiction of  
incorporation or organization)

88-0380546  
(I.R.S. Employer  
Identification No.)

6295 Northam Drive, Unit 8  
Mississauga, Ontario L4V 1WB  
(Address of Principal Executive Offices)

(905) 673-8501  
(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 or the Exchange Act. (Check one):

Large Accelerated filer

Accelerated Filer

Non-Accelerated Filer

Smaller Reporting Company

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

As of June 6, 2012 the Registrant had the following number of shares of its capital stock outstanding: 31,449,239 shares of Common Stock and 1 share of Series 1 Preferred Voting Stock, par value \$0.0001, representing 14 exchangeable shares of the Registrant's subsidiary, CardioGenics ExchangeCo Inc., which are exchangeable into 24,176,927 shares of the Registrant's Common Stock.

**CARDIOGENICS HOLDINGS INC.**

**FORM 10-Q**

**For the Quarter Ended April 30, 2012**

**INDEX**

	<b>Page</b>
<b><i>Part I. Financial Information</i></b>	<b>3</b>
Item 1: Financial Statements (Unaudited)	3
Condensed Consolidated Balance Sheets at April 30, 2012 (Unaudited) and October 31, 2011	3
Condensed Consolidated Statements of Operations (Unaudited) for the Six Months ended April 30, 2012 and 2011 and Cumulative from November 20, 1997 (Date of Inception) to April 30, 2012	4
Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficiency) (Unaudited) for the Six Months ended April 30, 2012	5
Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months ended April 30, 2012 and 2011 and Cumulative from November 20, 1997 (Date of Inception) to April 30, 2012	6
Notes to Condensed Consolidated Financial Statements (Unaudited)	7
Item 2: Management's Discussion and Analysis	12
Item 3: Quantitative and Qualitative Disclosures About Market Risk	15
Item 4: Controls and Procedures	15
<b><i>Part II. Other Information</i></b>	<b>16</b>
Item 1: Legal Proceedings	16
Item 1A: Risk Factors	17
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds	17
Item 3: Defaults Upon Senior Securities	17
Item 4: Removed and Reserved	17
Item 5: Other Information	17
Item 6: Exhibits	17
<i>Signatures</i>	18

**CardioGenics Holdings Inc.**  
**(A Development Stage Company)**  
**Condensed Consolidated Balance Sheets**

**PART I. FINANCIAL INFORMATION**

Item 1. Financial Statements (Unaudited)

	<u>April 30,</u> <u>2012</u>	<u>October 31,</u> <u>2011</u>
	(Unaudited)	(Note 2)
<b>Assets</b>		
<b>Current Assets</b>		
Cash and Cash Equivalents	\$ 271,951	\$ 669,202
Accounts Receivable	2,908	9,002
Deposits and Prepaid Expenses	51,998	51,541
Refundable Taxes Receivable	26,105	35,191
Investment Tax Credits Receivable	<u>193,618</u>	<u>187,497</u>
	<u>546,580</u>	<u>952,433</u>
Property and Equipment, net	77,107	82,308
Patents, net	<u>128,781</u>	<u>130,732</u>
	<u>205,888</u>	<u>213,040</u>
<b>Total Assets</b>	<u>\$ 752,468</u>	<u>\$ 1,165,473</u>
<b>Liabilities and Equity</b>		
<b>Current Liabilities</b>		
Accounts Payable and Accrued Expenses	\$ 633,379	\$ 596,692
Funds Held in Trust for Redemption of Class B Common Shares	4	4
Current Portion of Capital Lease Obligation	14,599	25,711
Due to Shareholders	<u>262,500</u>	<u>—</u>
	<u>910,482</u>	<u>622,407</u>
<b>Long Term Liabilities</b>		
Capital Lease Obligation, net of current portion	<u>—</u>	<u>2,630</u>
<b>Total Liabilities</b>	<u>910,482</u>	<u>625,037</u>
Commitments and Contingent Liabilities		
<b>Equity</b>		
Preferred stock; par value \$.0001 per share, 5,000,000 shares authorized, 1 issued and outstanding as at April 30, 2012 and October 31, 2011	<u>—</u>	<u>—</u>
Common stock; par value \$.00001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at April 30, 2012 and October 31, 2011 respectively	540	540
Additional paid-in capital	41,774,001	41,774,001
Deficit accumulated during development stage	(41,437,846)	(40,731,174)
Accumulated other comprehensive loss	<u>(160,754)</u>	<u>(173,407)</u>
Total CardioGenics Holdings Inc. equity	175,941	869,960
Non-controlling interest	<u>(333,955)</u>	<u>(329,524)</u>
Total equity (deficiency)	<u>(158,014)</u>	<u>540,436</u>
Total liabilities and equity	<u>\$ 752,468</u>	<u>\$ 1,165,473</u>

See notes to condensed consolidated financial statements.

**CardioGenics Holdings Inc.**  
**(A Development Stage Company)**  
**Condensed Consolidated Statements of Operations (unaudited)**  
**For the Three and Six Months Ended April 30, 2012 and 2011 and**  
**Cumulative from November 20, 1997 (Date of Inception) to April 30, 2012**

	For the three months Ended		For the six months Ended		Cumulative From November 20, 1997 (Date of Inception) to April 30, 2012
	April 30,		April 30,		
	2012	2011	2012	2011	
<b>Revenue</b>	\$ —	\$ —	\$ 1,136	\$ —	\$ 10,012
<b>Operating Expenses</b>					
Depreciation of Property and Equipment	4,539	4,871	9,094	9,529	210,533
Amortization of Patent Application Costs	1,260	1,090	2,560	2,132	14,971
Write-off of Patent Application Costs	—	—	—	—	214,625
General and Administrative	187,325	383,837	361,488	680,649	7,950,178
Write-off of Goodwill	—	—	—	—	12,780,214
Research and Product Development, Net of Investment Tax Credits	192,694	234,646	348,738	393,570	4,062,496
Cost of Settlement of Lawsuit	—	—	—	—	1,753,800
<b>Total operating expenses</b>	<u>385,818</u>	<u>624,444</u>	<u>721,880</u>	<u>1,085,880</u>	<u>26,986,817</u>
<b>Operating Loss</b>	<u>(385,818)</u>	<u>(624,444)</u>	<u>(720,744)</u>	<u>(1,085,880)</u>	<u>(26,976,805)</u>
<b>Other Expenses (Income)</b>					
Interest Expense and Bank Charges (Net)	6,014	4,296	9,485	8,900	2,146,121
Loss on Change in Value of Derivative Liability	—	—	—	—	12,421,023
Loss (Gain) on Foreign Exchange Transactions	<u>2,238</u>	<u>91,633</u>	<u>(19,126)</u>	<u>132,163</u>	<u>190,139</u>
<b>Total other expenses (income)</b>	<u>8,252</u>	<u>95,929</u>	<u>(9,641)</u>	<u>141,063</u>	<u>14,757,283</u>
<b>Loss from Continuing Operations</b>	(394,070)	(720,373)	(711,103)	(1,226,943)	(41,734,088)
<b>Discontinued Operations</b>					

Gain on Sale of Subsidiary	—	—	—	—	90,051
Loss from Discontinued Operations	—	—	—	—	(127,762)
<b>Net Loss</b>	<u>(394,070)</u>	<u>(720,373)</u>	<u>(711,103)</u>	<u>(1,226,943)</u>	<u>(41,771,799)</u>
<b>Net Loss attributable to non-controlling interest</b>	<u>(2,368)</u>	<u>(4,688)</u>	<u>(4,431)</u>	<u>(8,212)</u>	<u>(333,955)</u>
<b>Net Loss attributable to CardioGenics Holdings Inc.</b>	<u>\$ (391,702)</u>	<u>\$ (715,685)</u>	<u>\$ (706,672)</u>	<u>\$ (1,218,731)</u>	<u>\$ (41,437,844)</u>
<b>Basic and Fully Diluted Net Loss per Common Share attributable to CardioGenics Holdings Inc. Shareholders</b>	\$ (0.01)	\$ (0.01)	\$ (0.01)	\$ (0.02)	
<b>Weighted-average shares of Common Stock outstanding</b>	55,626,166	54,036,505	55,626,166	53,746,365	

See notes to condensed consolidated financial statements.

**CarioGenics Holdings Inc.**  
**(A Development Stage Company)**  
**Condensed Consolidated Statements of Changes in Equity (unaudited)**  
**For the six months ended April 30, 2012**

---

	<u>Common Stock</u>		<u>Additional Paid-in Capital</u>	<u>Deficit Accumulated During the Development Stage</u>	<u>Accumulated Other Comprehensive Income (Loss)</u>	<u>Noncontrolling Interest</u>	<u>Total Equity (Deficiency)</u>
	<u>Shares</u>	<u>Amount</u>					
<b>Balance October 31, 2011</b>	55,626,166	\$ 540	\$ 41,774,001	\$ (40,731,174)	\$ (173,407)	\$ (329,524)	\$ 540,436
Net loss attributable to noncontrolling interest						(4,431)	(4,431)
Comprehensive Income (Loss):							
Net Loss				(706,672)			(706,672)
Other Comprehensive Income							
Currency Translation Adjustment					12,653		12,653
Total Comprehensive (Loss)							(694,019)
<b>Balance at April 30, 2012</b>	<u>55,626,166</u>	<u>\$ 540</u>	<u>\$ 41,774,001</u>	<u>\$ (41,437,846)</u>	<u>\$ (160,754)</u>	<u>\$ (333,955)</u>	<u>\$ (158,014)</u>

See notes to condensed consolidated financial statements.



**CardioGenics Holdings Inc.**  
**(A Development Stage Company)**  
**Condensed Consolidated Statements of Cash Flows (unaudited)**  
**Six Months Ended April 30, 2012 and 2011 and**  
**Cumulative from November 20, 1997 (Date of Inception) to April 30, 2012**

	<b>Six Months Ended April 30</b>		<b>Cumulative from November 20, 1997 (Date of Inception) To April 30, 2012</b>
	<b>2012</b>	<b>2011</b>	
<b>Cash flows from operating activities</b>			
Net Loss for the Period	\$ (711,103)	\$ (1,226,943)	\$ (41,771,799)
Adjustments to reconcile net loss for the period to net cash used in operating activities			
Depreciation of Property and Equipment	9,094	9,529	210,533
Amortization of Patent Application Costs	2,560	2,132	14,971
Write-off of Patent Application Costs	—	—	214,625
Write-off of Goodwill	—	—	12,780,214
Amortization of Deferred Debt Issuance Costs	—	—	511,035
Loss on Extinguishment of Debt	—	—	275,676
Loss on Change in Value of Derivative Liability	—	—	12,421,023
Interest Accrued and Foreign Exchange Loss on Debt	—	—	922,539
Unrealized Foreign Currency Exchange Gains	—	—	25,092
Beneficial Conversion Charge included in Interest Expense	—	—	452,109
Re-pricing of Options for Services Rendered	—	163,750	163,750
Common Stock and Warrants issued on Settlement Of Lawsuit	—	—	1,653,800
Common Stock Issued as Employee or Officer/Director Compensation	—	—	2,508,282
Common Stock Issued for Services Rendered	—	100,000	2,726,262
Stock Options Issued for Services Rendered	—	—	192,238
Stock Options Issued to Directors and Committee Chairman	—	—	54,582
Changes in Operating Assets and Liabilities, Net of Acquisition			
Accounts Receivable	6,094	—	(2,908)
Share Subscriptions Receivable	—	115,000	—
Deposits and Prepaid Expenses	(457)	35,502	(51,209)
Refundable Taxes Receivable	9,086	(17,170)	(25,241)
Investment Tax Credits Receivable	(6,121)	156,482	(173,556)
Accounts Payable and Accrued Expenses	36,687	(90,830)	(134,533)
Advances	—	—	131
Cash used in operating activities	<u>(654,160)</u>	<u>(752,548)</u>	<u>(7,032,384)</u>
<b>Cash flows from investing activities</b>			
Cash Acquired from Acquisition	—	—	195,885
Purchase of Property and Equipment	(3,893)	—	(223,559)
Patent Application Costs	(609)	—	(315,179)
Cash used in investing activities	<u>(4,502)</u>	<u>—</u>	<u>(342,853)</u>
<b>Cash flows from financing activities</b>			
Repayment of Capital Lease Obligations Due to Shareholders	(13,742)	(7,205)	(29,318)
Due to Director	262,500	—	262,500
Issue of Debentures	—	(170)	725,330
Issue of Common Shares on Exercise of Stock options	—	2,750	2,781
Issue of Common Shares on Exercise of Warrants	—	—	45,652
Issue of Common Shares for Cash	—	359,412	5,624,169
Refund of Share Subscription	—	(15,378)	(15,000)
Redemption of 10% Senior Convertible Debentures	—	—	(394,972)
Cash provided by financing activities	<u>248,758</u>	<u>339,409</u>	<u>7,599,447</u>

<b>Effect of foreign exchange on cash and cash equivalents</b>	<u>12,653</u>	<u>131,526</u>	<u>47,741</u>
<b>Cash and Cash Equivalents</b>			
<b>Increase (decrease) in cash and cash equivalents during the period</b>	(397,251)	(281,613)	271,951
<b>Beginning of Period</b>	<u>669,202</u>	<u>1,844,752</u>	<u>—</u>
<b>End of Period</b>	<u>\$ 271,951</u>	<u>\$ 1,563,139</u>	<u>\$ 271,951</u>

## 1. Nature of Business

CardioGenics Inc. (“CardioGenics”) was incorporated on November 20, 1997 in the Province of Ontario, Canada, and carries on the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. CardioGenics has several test products that are in various stages of development.

CardioGenics’ business is that of a development-stage company, with a limited history of operations and whose revenues, to date, have been primarily comprised of grant revenue and Scientific Research Tax Credits from government agencies. There can be no assurance that the Company will be successful in obtaining regulatory approval for the marketing of any of the existing or future products that the Company will succeed in developing.

On October 27, 2009, the name of the Company was changed from JAG Media Holdings, Inc. to CardioGenics Holdings Inc.

## 2. Basis of Presentation

In the opinion of management, the unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the condensed interim consolidated financial position of CardioGenics Holdings Inc. and its subsidiaries under generally accepted accounting principles in the United States (“US GAAP”) as of April 30, 2012, their results of operations for the three and six months ended April 30, 2012 and 2011, and the period from November 20, 1997 (date of inception) to April 30, 2012, changes in equity for the six months ended April 30, 2012 and cash flows for the six months ended April 30, 2012 and 2011, and the period from November 20, 1997 (date of inception) to April 30, 2012. CardioGenics Holdings Inc. and its subsidiaries are referred to together herein as the “Company”. Pursuant to rules and regulations of the SEC, certain information and disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these consolidated financial statements unless significant changes have taken place since the end of the most recent fiscal year. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the consolidated financial statements, notes to consolidated financial statements and the other information in the audited consolidated financial statements of the Company as of October 31, 2011 and 2010 (the “Audited Financial Statements”) included in the Company’s Form 10-K/A that was previously filed with the SEC on April 13, 2012 and from which the October 31, 2011 consolidated balance sheet was derived.

The results of the Company’s operations for the six months ended April 30, 2012 are not necessarily indicative of the results of operations to be expected for the full year ending October 31, 2012.

The accompanying condensed interim consolidated financial statements have been prepared using the accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

The Company has incurred operating losses and has experienced negative cash flows from operations since inception. The Company has an accumulated deficit at April 30, 2012 of approximately \$41.4 million. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company has funded its activities to date almost exclusively from debt and equity financings. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of its products, and to commence sales and marketing efforts, if the FDA and other regulatory approvals are obtained. In order to meet its operating cash flow requirements Management's plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments. Management is also actively pursuing industry collaboration activities including product licensing and specific project financing.

While the Company believes it will be successful in obtaining the necessary financing to fund its operations, meet revenue projections and manage costs, there are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence.

### **3.Summary of Significant Accounting Policies**

#### **(a)Recent Accounting Pronouncements**

In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). The new standards are effective for annual periods beginning January 1, 2013, and interim periods within those annual periods. Retrospective application is required. The Company will implement the provisions of ASU 2011-11 beginning in fiscal 2014.

In June 2011, the FASB issued ASU 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. Under this ASU, an entity will have the option to present the components of net income and comprehensive income in either one or two consecutive financial statements. The ASU eliminates the option in U.S. GAAP to present other comprehensive income in the statement of changes in equity. An entity should apply the ASU retrospectively. Early adoption is permitted. The Company plans to implement the provisions of ASU 2011-05 by presenting a separate statement of other comprehensive income following the statement of operations beginning in fiscal 2013.

#### **4. Income Taxes**

Based on the Company's evaluation, management has concluded that there are no significant tax positions requiring recognition in the condensed interim consolidated financial statements.

The Company has incurred losses in Canada since inception, which have generated net operating loss carryforwards for income tax purposes. The net operating loss carryforwards arising from Canadian sources as of April 30, 2012, approximated \$6,301,000 (2011 - \$8,983,000) which will expire from 2013 through 2032. All fiscal years except 2011 have been assessed as originally filed in Canadian jurisdictions.

As of April 30, 2012, the Company had net operating loss carryforwards from US sources of approximately \$40,652,000 available to reduce future Federal taxable income which will expire from 2019 through 2032. Returns for the years 2008 through 2011 are yet to be filed.

For the six months ended April 30, 2012 and 2011, the Company's effective tax rate differs from the statutory rate principally due to the net operating losses for which no benefit was recorded.

## 5. Due to Shareholders

In February 2012 the Company received \$262,500 for the subscription of 1,050,000 of the Company's common stock. To date, the common stock has not been issued to the subscribers as the Company is not authorized to issue any additional common stock.

## 6. Stock Based Compensation

Stock-based employee compensation related to stock options for the six months ended April 30, 2012 and 2011 amounted to \$-0-.

The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:

	<u>Options</u>	<b>Weighted Average Exercise Price</b>
Outstanding - October 31, 2010	305,000	\$ 2.34
Granted	—	—
Forfeited/Expired	—	—
Exercised	<u>275,000</u>	0.01
Outstanding - October 31, 2011	30,000	\$ 0.90
Granted	—	—
Forfeited/Expired	—	—
Exercised	—	—
Outstanding - April 30, 2012	<u>30,000</u>	\$ 0.90

Options typically vest immediately at the date of grant. As such, the Company does not have any unvested options or unrecognized compensation expense at April 30, 2012.

## 7.Warrants

Outstanding warrants are as follows:	April 30, 2012	October 31, 2011
<b>Warrants</b>		
Issued to subscribers to the debenture financing of 2003 and its related extension entitling the holder to purchase 1 common share of the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012	2,046,808	2,046,808
Issued to subscribers to the debenture financing of 2004 and its related extension entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012	1,021,654	1,021,654
Issued to agents for the debenture financings of 2003 and 2004 entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012	208,417	208,417
Issued to former employee entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012	136,220	136,220
Issued to consultants July 31, 2009, entitling the holder to purchase 1 common share of the Company at an exercise price of \$0.90 per share up to and including July 31, 2012	104,785	104,785
Issued to consultant August 1, 2009, entitling the holder to purchase 1 common share in the company at an exercise price of \$0.90 per common share up to and including July 31, 2017	287,085	287,085
Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.30 per common share up to and including August 23, 2016	250,000	250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.50 per common share up to and including August 23, 2016	250,000	250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.75 per common share up to and including August 23, 2016	500,000	500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$1.00 per common share up to and including August 23, 2016	500,000	500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.75 per common share up to and including August 23, 2016	500,000	500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of \$0.10 per common share up to and including March 20, 2013	1,500,000	1,500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of \$0.34 per common share up to and including March 20, 2013	1,500,000	1,500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of \$0.50 per common share up to and including March 20, 2013	1,000,000	1,000,000
Total Warrants outstanding	<u>9,804,969</u>	<u>9,804,969</u>

## 8.Issuance of Common Stock

During the six months ended April 30, 2012, the Company issued no common shares, except for 211,977 common shares which were exchanged for 211,977 exchangeable shares.

## 9.Net Loss per Share

The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings per share (EPS):

	Three Months Ended April 30,		Six Months Ended April 30,	
	<u>2012</u>	<u>2011</u>	<u>2012</u>	<u>2011</u>
Weighted-average shares - basic	55,626,166	54,036,505	55,626,166	53,746,365
Effect of dilutive securities	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>
Weighted-average shares - diluted	<u>55,626,166</u>	<u>54,036,505</u>	<u>55,626,166</u>	<u>53,746,365</u>

Basic EPS and diluted EPS for the three and six months ended April 30, 2012 and 2011 have been computed by dividing the net loss available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants and shares to be issued upon the exercise of the outstanding options and warrants representing 9,834,969 and 4,131,974 incremental shares respectively have been excluded from the six months ended April 30, 2012 and 2011 computation of diluted EPS as they are antidilutive given the net losses generated.

## 10. Commitments and Contingent Liabilities

### Lawsuits

On April 22, 2009, the Company was served with a statement of claim from a former employee claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in the Company, with an aggregate claim of \$514,000. The Company considers all the claims to be without any merit, has already delivered a statement of defense and intends to vigorously defend the action. If the matter eventually proceeds to trial, the Company does not expect to be found liable on any ground or for any cause of action.

## 11. Supplemental Disclosure of Cash Flow Information

	For the Six Months Ended April 30	
	2012	2011
Cash paid during the year for:		
Interest	\$ 9,358	\$ 5,441
Income taxes	\$ —	\$ —



## Item 2. Management's Discussion and Analysis

You should read this Management's Discussion and Analysis ("MD&A") in combination with the accompanying unaudited condensed interim consolidated financial statements and related notes as well as the audited consolidated financial statements and the accompanying notes to the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") included within the Company's Annual Report on Form 10-K/A filed on April 13, 2012.

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed interim consolidated financial statements, which have been prepared in accordance with U.S. GAAP for interim financial statements filed with the Securities and Exchange Commission.

### Critical Accounting Policies and Estimates

The preparation of these unaudited condensed interim consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to accounts receivable, equipment, stock-based compensation, income taxes and contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The accounting policies and estimates used as of October 31, 2011, as outlined in our previously filed Form 10-K/A, have been applied consistently for the six months ended April 30, 2012.

### Related Party Transactions

During the six months ended April 30, 2012, the Company received \$262,500 for the subscription of 1,050,000 of the Company's common stock. To date, the common stock has not been issued to the subscribers as the Company is not authorized to issue any additional common stock.

### Off-Balance Sheet arrangements

We are not party to any off-balance sheet arrangements.

### Results of operations

#### Six months ended April 30, 2012 as compared to six months ended April 30, 2011

	Six Months Ended April 30,		\$ Change
	2012	2011	
Revenue	\$ 1,136	\$ —	\$ 1,136
Operating expenses:			
Depreciation of property and equipment	9,094	9,529	(435)
Amortization of patent application costs	2,560	2,132	428
General and administrative expenses	361,488	680,649	(319,161)
Research and product development, net of investment tax credits	348,738	393,570	(44,832)
Total operating expenses	721,880	1,085,880	(364,000)
Operating Loss	720,744	1,085,880	(365,136)
Other expenses (income)			
Interest expense and bank charges, net	9,485	8,900	585
Loss (gain) on foreign exchange	(19,126)	132,163	(151,289)
Net loss	\$ 711,103	\$ 1,226,943	\$ (515,840)

## Revenues

During the six months ended April 30, 2012 and 2011 we generated revenues of 2012 - \$1,136 and 2011 - NIL respectively from sales of paramagnetic beads. We anticipate additional revenues from said sales during the balance of the year but cannot at this time estimate the quantum of sales.

## Operating expenses

Operating expenses include the costs to a) develop and patent a method for controlling the delivery of compounds to a chemical reaction; b) develop the QL Care Analyzer, a small, automated, robust and proprietary point of care testing device; and, c) custom paramagnetic beads through our proprietary method which improves their light collection. In addition, the Company is in the process of adapting test products for the Point Of Care ("POC") disposable, single-use cartridge-format. Detailed manufacturing specifications and costing have been created and custom manufacturers have been sourced.

## General and administrative expenses

General and administrative expenses consist primarily of compensation to officers, occupancy costs, professional fees, listing costs and other office expenses. The decrease in general and administrative expenses is attributable primarily to a decrease in consulting fees and a charge of 2012 - Nil and 2011 - \$163,750 due to re-pricing of options.

## Research and product development, net of investment tax credits

Research and development expenses consist primarily of salaries and wages paid to officers and employees engaged in those activities and supplies consumed therefor. The decrease in research and development expenses is attributable primarily to the decrease in staff engaged in R&D.

## Three months ended April 30, 2012 as compared to three months ended April 30, 2011

	Three Months Ended April 30,		\$ Change
	2012	2011	
Revenue	\$ —	\$ —	\$ —
Operating expenses:			
Depreciation of property and equipment	4,539	4,871	(332)
Amortization of patent application costs	1,260	1,090	170
General and administrative expenses	187,325	383,837	(196,512)
Research and product development, net of investment tax credits	192,694	234,646	(41,952)
Total operating expenses	385,818	624,444	(238,626)
Operating Loss	385,818	624,444	(238,626)
Other expenses (income)			
Interest expense and bank charges, net	6,014	4,296	1,718
Loss (gain) on foreign exchange	2,238	91,633	(89,395)
Net loss	\$ 394,070	\$ 720,373	\$ (326,303)

### *Revenues*

During the three months ended April 30, 2012 and 2011 we generated no revenues.

### *Operating expenses*

Operating expenses include the costs to a) develop and patent a method for controlling the delivery of compounds to a chemical reaction; b) develop the QL Care Analyzer, a small, automated, robust and proprietary point of care testing device; and, c) custom paramagnetic beads through our proprietary method which improves their light collection. In addition, the Company is in the process of adapting test products for the POC disposable, single-use cartridge-format. Detailed manufacturing specifications and costing have been created and custom manufacturers have been sourced.

### *General and administrative expenses*

General and administrative expenses consist primarily of compensation to officers, occupancy costs, professional fees, listing costs and other office expenses. The decrease in general and administrative expenses is attributable primarily to a decrease in consulting fees and a charge of 2012 - Nil and 2011 - \$163,750 due to re-pricing of options.

### *Research and product development, net of investment tax credits*

Research and development expenses consist primarily of salaries and wages paid to officers and employees engaged in those activities and supplies consumed therefor. The decrease in research and development expenses is attributable primarily to the decrease in staff engaged in R&D.

### *Liquidity and Capital Resources*

We have not generated significant revenues since inception. We incurred a net loss of approximately \$711,000 and a cash flow deficiency from operating activities of \$654,160 for the six months ended April 30, 2012. We have not yet established an ongoing source of revenues sufficient to cover our operating costs and allow us to continue as a going concern. We have funded our activities to date almost exclusively from debt and equity financings. These matters raise substantial doubt about our ability to continue as a going concern.

We will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of our products, to fund the ongoing operations and to commence sales and marketing efforts. Our plans include financing activities such as private placements of our common stock and issuances of convertible debt instruments. We are also actively pursuing industry collaboration including product licensing and specific project financing.

We believe we will be successful in obtaining the necessary financing to fund our operations, meet revenue projections and manage costs; however, there are no assurances that such additional funding will be achieved and that we will succeed in obtaining the funding to support our future operations.

### *Seasonality*

We do not believe that our business is subject to seasonal trends or inflation. On an ongoing basis, we will attempt to minimize any effect of inflation on our operating results by controlling operating costs.

### *Recent Accounting Pronouncements*

The FASB had issued certain accounting pronouncements as of April 30, 2012 that will become effective in subsequent periods; however, we do not believe that any of those pronouncements would have significantly affected our financial accounting measurements or disclosures had they been in effect during the six months ended April 30, 2012 and 2011 or that they will have a significant effect at the time they become effective.

### Item 3. Quantitative and Qualitative Disclosure About Market Risk

N/A.

### Item 4. Controls and Procedures

#### (a) Evaluation of Disclosure Controls and Procedures:

Management is responsible for establishing and maintaining adequate disclosure controls and procedures and internal control over financial reporting (as defined in the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. A control system, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Because of the inherent limitations in all control systems, internal controls over financial reporting may not prevent or detect misstatements. The design and operation of a control system must also reflect that there are resource constraints and management is necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible controls.

Our management assessed the effectiveness of our disclosure controls and procedures and internal control over financial reporting for the quarter ended April 30, 2012 based on the criteria established in *Internal Control-Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on such assessment, our management concluded that during the period covered by this report, our disclosure controls and procedures and internal control over financial reporting were not effective. Management has identified the following material weaknesses in our disclosure controls and procedures and internal control over financial reporting:

- lack of documented policies and procedures;
- there is no effective separation of duties, which includes monitoring controls, between the members of management; and,
- lack of resources to account for complex and unusual transactions.

Management is currently evaluating what steps can be taken in order to address these material weaknesses.

#### (b) Changes in Internal Control over Financial Reporting:

During the quarter ended April 30, 2012, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II. OTHER INFORMATION

### Item 1. Legal Proceedings

On April 22, 2009, CardioGenics was served with a statement of claim in the Province of Ontario, Canada, from a prior contractor claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in CardioGenics, with an aggregate claim of \$514,000. The Company considers all the claims to be without any merit, has already delivered a statement of defence and intends to vigorously defend the action. If the matter eventually proceeds to trial, the Company does not expect to be found liable on any ground or for any cause of action.

On January 14, 2010, Flow Capital Advisors Inc. (“Flow Capital”) filed a lawsuit against JAG Media Holdings Inc. in the Circuit Court of the 17<sup>th</sup> Judicial Circuit In and For Broward County Florida (Case No. 10001713) (the “Flow Capital State Action”). Pursuant to this lawsuit, Flow Capital alleges that JAG Media Holdings breached a Non-Circumvention Agreement it had entered into with Flow Capital, dated January 1, 2004.

On January 15, 2010 Flow Capital filed a lawsuit against CardioGenics Inc., and another defendant in the United States District Court for the Southern District of Florida, Fort Lauderdale Division (Case No. 10-CV-60066-Martinez-Brown) (the “Flow Capital Federal Action”). This lawsuit alleges that CardioGenics (i) breached a Finder’s Fee Agreement in connection with the CardioGenics Acquisition; and (ii) breached a non-circumvention agreement. Flow Capital is claiming that it is entitled to the finder’s fee equal to eight percent (8%) of the JAG Media Holdings shares received by CardioGenics, or the equivalent monetary value of the stock. Plaintiff subsequently amended its complaint to add related tort claims.

Pursuant to applicable federal court rules, the parties to the Flow Capital Federal Action participated in a court mandated mediation session on August 17, 2011 where the parties attempted to settle their disputes. At the mediation, the parties agreed to a settlement of all claims as described below, subject to the approval of the Board of Directors of CardioGenics Holdings Inc., which approval was subsequently obtained. Pursuant to the settlement agreement, Flow Capital agreed to dismiss, with prejudice, the Flow Capital Federal Action and the Flow Capital State Action and CardioGenics agreed to issue Flow Capital 1,000,000 shares of restricted CardioGenics Holdings common stock and warrants to purchase restricted CardioGenics Holdings common stock as follows:

Type of Warrant	Number of Shares	Exercise Price	Vesting Date	Term
Cash Exercise Only	250,000	\$ 0.30/share	immediate	5 years
Cash Exercise Only	250,000	\$ 0.50/share	immediate	5 years
Cash Exercise Only	500,000	\$ 0.75/share	immediate	5 years
Cash Exercise Only	500,000	\$ 1.00/share	immediate	5 years
Cash or Cashless Exercise	500,000	\$ 0.75/share	August 1, 2012	5 years

The restricted shares of common stock and the warrants are subject to the rights and restrictions of Rule 144 and do not have any registration rights. As part of the settlement, the parties also exchanged mutual general releases and CardioGenics Holdings agreed to pay Flow Capital, in three monthly installments, \$100,000 for Flow Capital’s legal fees.

On August 23, 2011, the Company’s Board of Directors approved the settlement. As a result, the Company recorded a charge to the Condensed Statement of Operations at July 31, 2011 of \$1,753,800 for Cost of Settlement of Lawsuit, which amount is included in Accounts Payable and Accrued Expenses at July 31, 2011.

On October 26, 2010 Karver International Inc. filed a lawsuit in the 11<sup>th</sup> Judicial Circuit in and for Miami-Dade County, Florida against CardioGenics Holdings Inc. and several other defendants including affiliates, officers and directors of CardioGenics Holdings, Inc. The Plaintiff generally alleges that the named defendants made certain alleged misrepresentations in connection with the purchase of shares of CardioGenics Holdings Inc. On December 20, 2010 CardioGenics Holdings Inc. and other defendants filed a motion to dismiss on the basis that the court lacks personal jurisdiction over most defendants, that an enforceable forum selection clause requires that the action be litigated in Ontario, Canada that the doctrine of *forum non conveniens* requires dismissal in favor of the Ontario forum, and that the complaint suffers from numerous other technical deficiencies warranting dismissal (e.g., failure to attach documents to the Complaint, failure to plead fraud with particularity, etc.). In addition, prior to the motion being heard, Karver’s attorney filed a motion to withdraw as counsel for Karver. The court granted Karver’s attorney’s motion to withdraw and Karver had until approximately April 26, 2011 to engage new counsel. On April 20, 2011, having not engaged new counsel as of that date, Karver filed with the court a Notice of Voluntary Dismissal Without Prejudice, which dismisses the lawsuit against the named defendants without prejudice to Karver’s rights to recommence the action.

**Item 1A. Risk Factors**

Not Applicable

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None

**Item 3. Defaults Upon Senior Securities**

None

**Item 4. (Removed and Reserved)**

None

**Item 5. Other Information**

None

**Item 6. Exhibits**

31.1 Section 302 Certification of Chief Executive Officer

31.2 Section 302 Certification of Chief Financial Officer

32.1 Section 906 Certification of Chief Executive Officer and Chief Financial Officer

101 The following materials from CardioGenics Holdings Inc.'s Form 10-Q for the quarter ended April 30, 2012 in eXtensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets at April 30, 2012 (Unaudited) and October 31, 2011, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the Six Months ended April 30, 2012 and 2011 and Cumulative from November 20, 1997 (Date of Inception) to April 30, 2012, (iii) Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficiency) (Unaudited) for the Six Months ended April 30, 2012, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months ended April 30, 2012 and 2011 and Cumulative from November 20, 1997 (Date of Inception) to April 30, 2012, and (v) Notes to Condensed Consolidated Financial Statements (Unaudited)\*

---

\*Pursuant to Rule 406T of SEC Regulation S-T, the Interactive Data Files submitted electronically as Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of the Securities Act of 1933, as amended, are deemed not filed for purposes of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

## SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### CARDIOGENICS HOLDINGS INC.

Date: June 12, 2012

By: /s/ Yahia Gawad  
Name: Yahia Gawad  
Title: Chief Executive Officer

Date: June 12, 2012

By: /s/ James Essex  
Name: James Essex  
Title: Chief Financial Officer

## EXHIBIT INDEX

- 31.1 Section 302 Certification of Chief Executive Officer
- 31.2 Section 302 Certification of Chief Financial Officer
- 32.1 Section 906 Certification of Chief Executive Officer and Chief Financial Officer
- 101 The following materials from CardioGenics Holdings Inc.'s Form 10-Q for the quarter ended April 30, 2012 in eXtensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets at April 30, 2012 (Unaudited) and October 31, 2011, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the Six Months ended April 30, 2012 and 2011 and Cumulative from November 20, 1997 (Date of Inception) to April 30, 2012, (iii) Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficiency) (Unaudited) for the Six Months ended April 30, 2012, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months ended April 30, 2012 and 2011 and Cumulative from November 20, 1997 (Date of Inception) to April 30, 2012, and (v) Notes to Condensed Consolidated Financial Statements (Unaudited)\*

---

\*Pursuant to Rule 406T of SEC Regulation S-T, the Interactive Data Files submitted electronically as Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of the Securities Act of 1933, as amended, are deemed not filed for purposes of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.



## SECTION 302 CERTIFICATION

I, Yahia Gawad, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended April 30, 2012 of CardioGenics Holdings Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in the report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 12, 2012

/s/ Yahia Gawad  
Yahia Gawad  
Chief Executive Officer

## SECTION 302 CERTIFICATION

I, James Essex, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended April 30, 2012 of CardioGenics Holdings Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in the report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 12, 2012

/s/ James Essex  
James Essex  
Chief Financial Officer

**Section 906 Certification by the Chief Executive Officer and Chief Financial Officer**

Each of Yahia Gawad, Chief Executive Officer, and James Essex, Chief Financial Officer, of CardioGenics Holdings Inc., a Nevada corporation (the "Company") hereby certifies pursuant to 18 U.S.C. ss. 1350, as added by ss. 906 of the Sarbanes-Oxley Act of 2002, that, to their knowledge:

- (1) The Company's periodic report on Form 10-Q for the period ended April 30, 2012 ("Form 10-Q") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operation of the Company.

*/s/ Yahia Gawad*

---

Name: Yahia Gawad  
Title: Chief Executive Officer

Date: June 12, 2012

*/s/ James Essex*

---

Name: James Essex  
Title: Chief Financial Officer

## Document and Entity Information

Document and Entity Information (USD \$)	6 Months Ended 04/30/2012	06/06/2012
Document Type	10-Q	
Amendment Flag	false	
Document Period End Date	2012-04-30	
Document Fiscal Year Focus	2,012	
Document Fiscal Period Focus	Q2	
Trading Symbol	CGNH	
Entity Registrant Name	CARDIOGENICS HOLDINGS INC.	
Entity Central Index Key	0001089029	
Current Fiscal Year End Date	--10-31	
Entity Filer Category	Smaller Reporting Company	
Entity Common Stock, Shares Outstanding		31,449,239

## Condensed Consolidated Balance Sheets

Condensed Consolidated Balance Sheets (USD \$)	04/30/2012	10/31/2011
Development Stage Enterprise Deficit Accumulated During Development Stage [Member]		
<b>Equity</b>		
Total equity (deficiency)	\$ (41,437,846)	\$ (40,731,174)
Accumulated Other Comprehensive Income [Member]		
<b>Equity</b>		
Total equity (deficiency)	(160,754)	(173,407)
Additional Paid In Capital [Member]		
<b>Equity</b>		
Total equity (deficiency)	41,774,001	41,774,001
Common Stock [Member]		
<b>Equity</b>		
Total equity (deficiency)	540	540
Noncontrolling Interest [Member]		
<b>Equity</b>		
Total equity (deficiency)	(333,955)	(329,524)
<b>Assets</b>		
<b>Current Assets</b>		
Cash and Cash Equivalents	271,951	669,202
Accounts Receivable	2,908	9,002
Deposits and Prepaid Expenses	51,998	51,541
Refundable Taxes Receivable	26,105	35,191
Investment Tax Credits Receivable	193,618	187,497
Assets, Current, Total	546,580	952,433
Property and Equipment, net	77,107	82,308
Patents, net	128,781	130,732
Assets, Noncurrent, Total	205,888	213,040
Total Assets	752,468	1,165,473
<b>Liabilities and Equity</b>		
<b>Current Liabilities</b>		
Accounts Payable and Accrued Expenses	633,379	596,692
Funds Held in Trust for Redemption of Class B Common Shares	4	4
Current Portion of Capital Lease Obligation	14,599	25,711
Due to Shareholders	262,500	0
Liabilities, Current, Total	910,482	622,407
<b>Long Term Liabilities</b>		
Capital Lease Obligation, net of current portion	0	2,630
Total Liabilities	910,482	625,037
Commitments and Contingent Liabilities		
<b>Equity</b>		
Preferred stock; par value \$.0001 per share, 5,000,000 shares authorized, 1 issued and outstanding as at April 30, 2012 and October 31, 2011	0	0
Common stock; par value \$.00001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at April 30, 2012 and October 31, 2011 respectively	540	540
Additional paid-in capital	41,774,001	41,774,001

Deficit accumulated during development stage	(41,437,846)	(40,731,174)
Accumulated other comprehensive loss	(160,754)	(173,407)
Total CardioGenics Holdings Inc. equity	<u>175,941</u>	<u>869,960</u>
Non-controlling interest	(333,955)	(329,524)
Total equity (deficiency)	(158,014)	540,436
Total liabilities and equity	<u>\$ 752,468</u>	<u>\$ 1,165,473</u>

### Condensed Consolidated Balance Sheets (Parenthetical)

Condensed Consolidated Balance Sheets (Parenthetical) (USD \$)	04/30/2012	10/31/2011
Exchangeable Shares [Member]		
Common stock, common shares issued	24,176,927	24,388,904
Common stock, common shares outstanding	24,176,927	24,388,904
Common Stock [Member]		
Common stock, common shares issued	31,449,239	31,237,262
Common stock, common shares outstanding	31,449,239	31,237,262
Preferred stock, par value	\$ 0.0001	\$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	1	1
Preferred stock, outstanding	1	1
Common stock, par value	\$ 0.00001	\$ 0.00001
Common stock, shares authorized	65,000,000	65,000,000

## Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Operations (USD \$)	3 Months Ended 04/30/2012	6 Months Ended 04/30/2012	6 Months Ended 04/30/2011	04/30/2012	3 Months Ended 04/30/2011
Development Stage Enterprise Deficit Accumulated During Development Stage [Member]					
Net Loss attributable to CardioGenics Holdings Inc.		\$ (706,672)			
Noncontrolling Interest [Member]					
Net Loss attributable to non-controlling interest		(4,431)			
Revenue	0	1,136	0	10,012	0
<b>Operating Expenses</b>					
Depreciation of Property and Equipment	4,539	9,094	9,529	210,533	4,871
Amortization of Patent Application Costs	1,260	2,560	2,132	14,971	1,090
Write-off of Patent Application Costs	0	0	0	214,625	0
General and Administrative	187,325	361,488	680,649	7,950,178	383,837
Write-off of Goodwill	0	0	0	12,780,214	0
Research and Product Development, Net of Investment Tax Credits	192,694	348,738	393,570	4,062,496	234,646
Cost of Settlement of Lawsuit	0	0	0	1,753,800	0
Total operating expenses	<u>385,818</u>	<u>721,880</u>	<u>1,085,880</u>	<u>26,986,817</u>	<u>624,444</u>
Operating Loss	<u>(385,818)</u>	<u>(720,744)</u>	<u>(1,085,880)</u>	<u>(26,976,805)</u>	<u>(624,444)</u>
<b>Other Expenses (Income)</b>					
Interest Expense and Bank Charges (Net)	6,014	9,485	8,900	2,146,121	4,296
Loss on Change in Value of Derivative Liability	0	0	0	12,421,023	0
Loss (Gain) on Foreign Exchange Transactions	2,238	(19,126)	132,163	190,139	91,633
Total other expenses (income)	<u>8,252</u>	<u>(9,641)</u>	<u>141,063</u>	<u>14,757,283</u>	<u>95,929</u>
Loss from Continuing Operations	<u>(394,070)</u>	<u>(711,103)</u>	<u>(1,226,943)</u>	<u>(41,734,088)</u>	<u>(720,373)</u>
<b>Discontinued Operations</b>					
Gain on Sale of Subsidiary	0	0	0	90,051	0
Loss from Discontinued Operations	0	0	0	(127,762)	0
Net Loss	<u>(394,070)</u>	<u>(711,103)</u>	<u>(1,226,943)</u>	<u>(41,771,799)</u>	<u>(720,373)</u>
Net Loss attributable to non-controlling interest	(2,368)	(4,431)	(8,212)	(333,955)	(4,688)
Net Loss attributable to CardioGenics Holdings Inc.	<u>\$ (391,702)</u>	<u>\$ (706,672)</u>	<u>\$ (1,218,731)</u>	<u>\$ (41,437,844)</u>	<u>\$ (715,685)</u>
Basic and Fully Diluted Net Loss per Common Share attributable to CardioGenics Holdings Inc. Shareholders	<u>\$ (0.01)</u>	<u>\$ (0.01)</u>	<u>\$ (0.02)</u>		<u>\$ (0.01)</u>
Weighted-average shares of Common Stock outstanding	55,626,166	55,626,166	53,746,365		54,036,505



## Condensed Consolidated Statements of Changes in Equity

Condensed Consolidated Statements of Changes in Equity (USD \$)	6 Months Ended 04/30/2012	04/30/2012
Development Stage Enterprise Deficit Accumulated During Development Stage [Member]		
Beginning Balance	\$ (40,731,174)	
<b>Comprehensive Income (Loss):</b>		
Net Loss	(706,672)	
Ending Balance	(41,437,846)	(41,437,846)
Accumulated Other Comprehensive Income [Member]		
Beginning Balance	(173,407)	
<b>Other Comprehensive Income</b>		
Currency Translation Adjustment	12,653	
Ending Balance	(160,754)	(160,754)
Additional Paid In Capital [Member]		
Beginning Balance	41,774,001	
Ending Balance	41,774,001	41,774,001
Common Stock [Member]		
Beginning Balance (in shares)	55,626,166	
Beginning Balance	540	
Ending Balance (in shares)	55,626,166	55,626,166
Ending Balance	540	540
Noncontrolling Interest [Member]		
Beginning Balance	(329,524)	
Net loss attributable to noncontrolling interest	(4,431)	
Ending Balance	(333,955)	(333,955)
Beginning Balance	540,436	
Net loss attributable to noncontrolling interest	(4,431)	(333,955)
<b>Comprehensive Income (Loss):</b>		
Net Loss	(706,672)	(41,437,844)
<b>Other Comprehensive Income</b>		
Currency Translation Adjustment	12,653	
Total Comprehensive (Loss)	<u>(694,019)</u>	
Ending Balance	\$ (158,014)	\$ (158,014)

## Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Cash Flows (USD \$)	6 Months Ended 04/30/2012	6 Months Ended 04/30/2011	04/30/2012
Goods And Services Exchanged For Equity Instrument [Member]			
<b>Adjustments to reconcile net loss for the period to net cash used in operating activities</b>			
Common Stock and Warrants issued	\$ 0	\$ 100,000	\$ 2,726,262
Stock Options Issued	0	0	192,238
Management [Member]			
<b>Adjustments to reconcile net loss for the period to net cash used in operating activities</b>			
Stock Options Issued	0	0	54,582
Settlement Of Litigation [Member]			
<b>Adjustments to reconcile net loss for the period to net cash used in operating activities</b>			
Common Stock and Warrants issued	0	0	1,653,800
<b>Cash flows from operating activities</b>			
Net Loss for the Period	(711,103)	(1,226,943)	(41,771,799)
<b>Adjustments to reconcile net loss for the period to net cash used in operating activities</b>			
Depreciation of Property and Equipment	9,094	9,529	210,533
Amortization of Patent Application Costs	2,560	2,132	14,971
Write-off of Patent Application Costs	0	0	214,625
Write-off of Goodwill	0	0	12,780,214
Amortization of Deferred Debt Issuance Costs	0	0	511,035
Loss on Extinguishment of Debt	0	0	275,676
Loss on Change in Value of Derivative Liability	0	0	12,421,023
Interest Accrued and Foreign Exchange Loss on Debt	0	0	922,539
Unrealized Foreign Currency Exchange Gains	0	0	25,092
Beneficial Conversion Charge included in Interest Expense	0	0	452,109
Re-pricing of Options for Services Rendered	0	163,750	163,750
Common Stock Issued as Employee or Officer/Director Compensation	0	0	2,508,282
<b>Changes in Operating Assets and Liabilities, Net of Acquisition</b>			
Accounts Receivable	6,094	0	(2,908)
Share Subscriptions Receivable	0	115,000	0
Deposits and Prepaid Expenses	(457)	35,502	(51,209)
Refundable Taxes Receivable	9,086	(17,170)	(25,241)
Investment Tax Credits Receivable	(6,121)	156,482	(173,556)
Accounts Payable and Accrued Expenses	36,687	(90,830)	(134,533)
Advances	0	0	131
Cash used in operating activities	(654,160)	(752,548)	(7,032,384)
<b>Cash flows from investing activities</b>			
Cash Acquired from Acquisition	0	0	195,885
Purchase of Property and Equipment	(3,893)	0	(223,559)
Patent Application Costs	(609)	0	(315,179)
Cash used in investing activities	(4,502)	0	(342,853)
<b>Cash flows from financing activities</b>			
Repayment of Capital Lease Obligations	(13,742)	(7,205)	(29,318)
Due to Shareholders	262,500	0	262,500

Due to Director	0	(170)	725,330
Issue of Debentures	0	0	1,378,305
Issue of Common Shares on Exercise of Stock options	0	2,750	2,781
Issue of Common Shares on Exercise of Warrants	0	0	45,652
Issue of Common Shares for Cash	0	359,412	5,624,169
Refund of Share Subscription	0	(15,378)	(15,000)
Redemption of 10% Senior Convertible Debentures	0	0	(394,972)
Cash provided by financing activities	<u>248,758</u>	<u>339,409</u>	<u>7,599,447</u>
Effect of foreign exchange on cash and cash equivalents	12,653	131,526	47,741
<b>Cash and Cash Equivalents</b>			
Increase (decrease) in cash and cash equivalents during the period	<u>(397,251)</u>	<u>(281,613)</u>	<u>271,951</u>
Beginning of Period	669,202	1,844,752	0
End of Period	\$ 271,951	\$ 1,563,139	\$ 271,951

## Nature of Business

Nature of Business (USD \$)	6 Months Ended 04/30/2012
--------------------------------	------------------------------

### Nature of Business **1.Nature of Business**

CardioGenics Inc. ("CardioGenics") was incorporated on November 20, 1997 in the Province of Ontario, Canada, and carries on the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. CardioGenics has several test products that are in various stages of development.

CardioGenics' business is that of a development-stage company, with a limited history of operations and whose revenues, to date, have been primarily comprised of grant revenue and Scientific Research Tax Credits from government agencies. There can be no assurance that the Company will be successful in obtaining regulatory approval for the marketing of any of the existing or future products that the Company will succeed in developing.

On October 27, 2009, the name of the Company was changed from JAG Media Holdings, Inc. to CardioGenics Holdings Inc.

## Basis of Presentation

Basis of Presentation (USD \$)	6 Months Ended 04/30/2012
-----------------------------------	------------------------------

Basis of Presentation **2. Basis of Presentation**

In the opinion of management, the unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the condensed interim consolidated financial position of CardioGenics Holdings Inc. and its subsidiaries under generally accepted accounting principles in the United States ("US GAAP") as of April 30, 2012, their results of operations for the three and six months ended April 30, 2012 and 2011, and the period from November 20, 1997 (date of inception) to April 30, 2012, changes in equity for the six months ended April 30, 2012 and cash flows for the six months ended April 30, 2012 and 2011, and the period from November 20, 1997 (date of inception) to April 30, 2012. CardioGenics Holdings Inc. and its subsidiaries are referred to together herein as the "Company". Pursuant to rules and regulations of the SEC, certain information and disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these consolidated financial statements unless significant changes have taken place since the end of the most recent fiscal year. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the consolidated financial statements, notes to consolidated financial statements and the other information in the audited consolidated financial statements of the Company as of October 31, 2011 and 2010 (the "Audited Financial Statements") included in the Company's Form 10-K/A that was previously filed with the SEC on April 13, 2012 and from which the October 31, 2011 consolidated balance sheet was derived.

The results of the Company's operations for the six months ended April 30, 2012 are not necessarily indicative of the results of operations to be expected for the full year ending October 31, 2012.

The accompanying condensed interim consolidated financial statements have been prepared using the accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

The Company has incurred operating losses and has experienced negative cash flows from operations since inception. The Company has an accumulated deficit at April 30, 2012 of approximately \$41.4 million. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company has funded its activities to date almost exclusively from debt and equity financings. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of its products, and to commence sales and marketing efforts, if the FDA and other regulatory approvals are obtained. In order to meet its operating cash flow requirements Management's plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments. Management is also actively pursuing industry collaboration activities including product licensing and specific project financing.

While the Company believes it will be successful in obtaining the necessary financing to fund its operations, meet revenue projections and manage costs, there are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence.

## Summary of Significant Accounting Policies

Summary of Significant Accounting Policies (USD \$)	6 Months Ended 04/30/2012
--------------------------------------------------------	------------------------------

Summary of Significant Accounting Policies **3.Summary of Significant Accounting Policies**

### (a)Recent Accounting Pronouncements

In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). The new standards are effective for annual periods beginning January 1, 2013, and interim periods within those annual periods. Retrospective application is required. The Company will implement the provisions of ASU 2011-11 beginning in fiscal 2014.

In June 2011, the FASB issued ASU 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. Under this ASU, an entity will have the option to present the components of net income and comprehensive income in either one or two consecutive financial statements. The ASU eliminates the option in U.S. GAAP to present other comprehensive income in the statement of changes in equity. An entity should apply the ASU retrospectively. Early adoption is permitted. The Company plans to implement the provisions of ASU 2011-05 by presenting a separate statement of other comprehensive income following the statement of operations beginning in fiscal 2013.

## Income Taxes

Income Taxes (USD \$)	6 Months Ended 04/30/2012
--------------------------	------------------------------

### Income Taxes **4. Income Taxes**

Based on the Company's evaluation, management has concluded that there are no significant tax positions requiring recognition in the condensed interim consolidated financial statements.

The Company has incurred losses in Canada since inception, which have generated net operating loss carryforwards for income tax purposes. The net operating loss carryforwards arising from Canadian sources as of April 30, 2012, approximated \$6,301,000 (2011 - \$8,983,000) which will expire from 2013 through 2032. All fiscal years except 2011 have been assessed as originally filed in Canadian jurisdictions.

As of April 30, 2012, the Company had net operating loss carryforwards from US sources of approximately \$40,652,000 available to reduce future Federal taxable income which will expire from 2019 through 2032. Returns for the years 2008 through 2011 are yet to be filed.

For the six months ended April 30, 2012 and 2011, the Company's effective tax rate differs from the statutory rate principally due to the net operating losses for which no benefit was recorded.

## Due to Shareholders

Due to Shareholders (USD \$)	6 Months Ended 04/30/2012
---------------------------------	------------------------------

Due to Shareholders **5.Due to Shareholders**

In February 2012 the Company received \$262,500 for the subscription of 1,050,000 of the Company's common stock. To date, the common stock has not been issued to the subscribers as the Company is not authorized to issue any additional common stock.



## Stock Based Compensation

Stock Based Compensation (USD \$)	6 Months Ended 04/30/2012
--------------------------------------	------------------------------

### Stock Based Compensation **6. Stock Based Compensation**

Stock-based employee compensation related to stock options for the six months ended April 30, 2012 and 2011 amounted to \$-0-.

The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:

	<b>Options</b>	<b>Weighted Average Exercise Price</b>
Outstanding – October 31, 2010	305,000	\$ 2.34
Granted	—	—
Forfeited/Expired	—	—
Exercised	275,000	\$ 0.01
Outstanding – October 31, 2011	30,000	\$ 0.90
Granted	—	—
Forfeited/Expired	—	—
Exercised	—	—
Outstanding – April 30, 2012	30,000	\$ 0.90

Options typically vest immediately at the date of grant. As such, the Company does not have any unvested options or unrecognized compensation expense at April 30, 2012.

## Warrants

Warrants (USD \$)	6 Months Ended 04/30/2012
----------------------	------------------------------

### Warrants 7.Warrants

Outstanding warrants are as follows:	<u>April 30, 2012</u>	<u>October 31, 2011</u>
<b>Warrants</b>		
Issued to subscribers to the debenture financing of 2003 and its related extension entitling the holder to purchase 1 common share of the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012	2,046,808	2,046,808
Issued to subscribers to the debenture financing of 2004 and its related extension entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012	1,021,654	1,021,654
Issued to agents for the debenture financings of 2003 and 2004 entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012	208,417	208,417
Issued to former employee entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012	136,220	136,220
Issued to consultants July 31, 2009, entitling the holder to purchase 1 common share of the Company at an exercise price of \$0.90 per share up to and including July 31, 2012	104,785	104,785
Issued to consultant August 1, 2009, entitling the holder to purchase 1 common share in the company at an exercise price of \$0.90 per common share up to and including July 31, 2017	287,085	287,085
Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.30 per common share up to and including August 23, 2016	250,000	250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.50 per common share up to and including August 23, 2016	250,000	250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.75 per common share up to and including August 23, 2016	500,000	500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$1.00 per common share up to and including August 23, 2016	500,000	500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.75 per common share up to and including August 23, 2016	500,000	500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of \$0.10 per common share up to and including March 20, 2013	1,500,000	1,500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of \$0.34 per common share up to and including March 20, 2013	1,500,000	1,500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of \$0.50 per common share up to and including March 20, 2013	<u>1,000,000</u>	<u>1,000,000</u>
Total Warrants outstanding	<u>9,804,969</u>	<u>9,804,969</u>

## Issuance of Common Stock

Issuance of Common Stock (USD \$)	6 Months Ended 04/30/2012
--------------------------------------	------------------------------

Issuance of Common Stock **8.Issuance of Common Stock**

During the six months ended April 30, 2012, the Company issued no common shares, except for 211,977 common shares which were exchanged for 211,977 exchangeable shares.

## Net Loss per Share

Net Loss per Share (USD \$)	6 Months Ended 04/30/2012
-----------------------------	---------------------------

Net Loss per Share **9.Net Loss per Share**

The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings per share (EPS):

	Three Months Ended		Six Months Ended	
	April 30,		April 30,	
	2012	2011	2012	2011
Weighted-average shares - basic	55,626,166	54,036,505	55,626,166	53,746,365
Effect of dilutive securities	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>
Weighted-average shares - diluted	<u>55,626,166</u>	<u>54,036,505</u>	<u>55,626,166</u>	<u>53,746,365</u>

Basic EPS and diluted EPS for the three and six months ended April 30, 2012 and 2011 have been computed by dividing the net loss available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants and shares to be issued upon the exercise of the outstanding options and warrants representing 9,834,969 and 4,131,974 incremental shares respectively have been excluded from the six months ended April 30, 2012 and 2011 computation of diluted EPS as they are antidilutive given the net losses generated.

## Commitments and Contingent Liabilities

Commitments and Contingent Liabilities  
(USD \$)

6 Months Ended  
04/30/2012

Commitments and Contingent Liabilities

### 10. Commitments and Contingent Liabilities

#### Lawsuits

On April 22, 2009, the Company was served with a statement of claim from a former employee claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in the Company, with an aggregate claim of \$514,000. The Company considers all the claims to be without any merit, has already delivered a statement of defense and intends to vigorously defend the action. If the matter eventually proceeds to trial, the Company does not expect to be found liable on any ground or for any cause of action.

## Supplemental Disclosure of Cash Flow Information

Supplemental Disclosure of Cash Flow Information  
(USD \$)

6 Months Ended  
04/30/2012

Supplemental Disclosure of Cash Flow Information

### 11. Supplemental Disclosure of Cash Flow Information

	For the Six Months Ended April 30	
	<u>2012</u>	<u>2011</u>
Cash paid during the year for:		
Interest	\$ 9,358	\$ 5,441
Income taxes	\$ —	\$ —

